Asia-Pacific multiple myeloma market to expand at 7.4% CAGR to 2021

The treatment market for multiple myeloma across the Asia-Pacific (APAC) countries of China, India, Japan, and Australia will rise in value from $1.7 billion in 2014 to $2.8 billion by 2021, representing a compound annual growth rate (CAGR) of 7.4%, new research forecasts.

According to business intelligence provider GBI Research’s latest report, that growth will primarily be driven by the emergence of novel therapeutics that have significantly improved clinical outcomes across all stages of the disease, as well as the lack of generic competition in China, Japan and Australia.

Deekshita Allavarapu, an analyst for GBI Research, expects the leading brands, Celgene’s (Nasdaq: CELG) Revlimid (lenalidomide), Millennium/Johnson & Johnson's (NYSE: JNJ) Velcade (bortezomib) and Thalomid (thalidomide), also from Celgene, to continue to perform strongly in the APAC multiple myeloma treatment space, with minimal generic competition at present.